Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F McDermott

Showing results (71-80 of 227) with videos related to

Pageof 23
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 9, 2015
Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinomaLaurence Albiges, André P Fay, Wanling Xie, et al.
European Urology|June 17, 2022
Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective StudiesRebecca E Graff, Kathryn M Wilson, Alejandro Sanchez, et al.
Journal for Immunotherapy of Cancer|February 8, 2022
Soluble PD-L1 as an early marker of progressive disease on nivolumabKathleen M Mahoney, Petra Ross-Macdonald, Long Yuan, et al.
European Urology|September 17, 2020
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell CarcinomaSumanta K Pal, Bernard J Escudier, Michael B Atkins, et al.
Investigational New Drugs|January 28, 2021
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapyToni K Choueiri, Michael B Atkins, Tracy L Rose, et al.
Cancer|June 11, 2015
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinomaM Dror Michaelson, Rana R McKay, Lillian Werner, et al.
BMC Cancer|October 27, 2023
Regulation of HHLA2 expression in kidney cancer and myeloid cellsTomonari Shigemura, Nahuel Perrot, Zimo Huang, et al.
Cancer|August 13, 2015
Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanomaElizabeth I Buchbinder, Jeffrey A Sosman, Donald P Lawrence, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinomaRobert J Motzer, Gary R Hudes, Brendan D Curti, et al.
Plos Genetics|September 27, 2018
Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinomaLana Hamieh, Toni K Choueiri, Barbara Ogórek, et al.
Pageof 23

Showing results (71-80 of 227) with videos related to

Sort By:
Pageof 23
European Journal of Cancer (Oxford, England : 1990)|September 9, 2015
Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinomaLaurence Albiges, André P Fay, Wanling Xie, et al.
European Urology|June 17, 2022
Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective StudiesRebecca E Graff, Kathryn M Wilson, Alejandro Sanchez, et al.
Journal for Immunotherapy of Cancer|February 8, 2022
Soluble PD-L1 as an early marker of progressive disease on nivolumabKathleen M Mahoney, Petra Ross-Macdonald, Long Yuan, et al.
European Urology|September 17, 2020
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell CarcinomaSumanta K Pal, Bernard J Escudier, Michael B Atkins, et al.
Investigational New Drugs|January 28, 2021
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapyToni K Choueiri, Michael B Atkins, Tracy L Rose, et al.
Cancer|June 11, 2015
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinomaM Dror Michaelson, Rana R McKay, Lillian Werner, et al.
BMC Cancer|October 27, 2023
Regulation of HHLA2 expression in kidney cancer and myeloid cellsTomonari Shigemura, Nahuel Perrot, Zimo Huang, et al.
Cancer|August 13, 2015
Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanomaElizabeth I Buchbinder, Jeffrey A Sosman, Donald P Lawrence, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinomaRobert J Motzer, Gary R Hudes, Brendan D Curti, et al.
Plos Genetics|September 27, 2018
Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinomaLana Hamieh, Toni K Choueiri, Barbara Ogórek, et al.
Pageof 23